Ganirelix
The injection that stops an IVF cycle ovulating early, and shortened the protocol from weeks to days
Ganirelix blocks the GnRH receptor directly, so it suppresses the pituitary within hours rather than the weeks an agonist needs. That single property rewrote IVF scheduling. The brands are gone from the US market; the drug continues as generics.
What is it?
A GnRH agonist suppresses the pituitary the long way round: it floods the receptor, causes a flare, and only then shuts it down, which takes a couple of weeks of daily injections before stimulation can even start. An antagonist blocks the receptor outright. Ganirelix does that, so the suppression starts the day it is given and stops when it is stopped.
The 250 mcg dose was chosen in a dose-finding trial. In 333 women stimulated with recombinant FSH, ganirelix was tested at six daily doses from 0.0625 to 2.0 mg; the lowest and highest groups were stopped early on independent advice. The 0.25 mg group had the highest implantation rate (21.9%) and an ongoing pregnancy rate of 33.8% per attempt, while the 1 and 2 mg groups had early miscarriage rates of 12% to 13% and the 2 mg group an implantation rate of 1.5%.
The trial that made the case randomised 730 women to ganirelix or a long buserelin protocol with recombinant FSH. The median duration of the GnRH drug was 5 days against 26, the median FSH dose was 1,500 IU against 1,800, and stimulation was a day shorter — with a slightly higher rate of LH rises on ganirelix, 2.8% against 1.3%. Ongoing pregnancy per attempt was 20.3% against 25.7%, and ovarian hyperstimulation syndrome 2.4% against 5.9%.
A North American trial compared ganirelix with a long leuprolide protocol. Leuprolide retrieved more eggs (14.1 against 11.6), fertilisation was the same (about 62%), and clinical pregnancy per attempt was 35.4% against 38.4%. Ganirelix needed a shorter course and fewer injections, and caused fewer moderate or severe injection-site reactions (11.9% and 0.6% against 24.4% and 1.1%). In a small pilot of 48 poor responders it appeared as effective as a microdose leuprolide protocol.
The label is narrow and the dose is fixed: 250 mcg under the skin once daily, started after FSH has run for a few days and continued until the day of the hCG trigger, to inhibit premature LH surges in controlled ovarian hyperstimulation. Later trials ask when to start it rather than whether to use it.
Under the skin it is absorbed rapidly, peaking about an hour after injection, with an elimination half-life of about 13 hours after one dose and 16 hours with daily dosing; steady state is reached after three days (label). The label lists no formal drug interaction studies and tells prescribers to exclude pregnancy before starting.
What is published about the offspring is reassuring as far as it goes. A follow-up of 333 women randomised across six ganirelix doses recorded 68 ongoing pregnancies, 73 infants, a 9% miscarriage rate and one major congenital anomaly — a preliminary report rather than a registry.
Its role is now being tested against cheaper alternatives. In a 2019 non-inferiority trial in egg donors, oral medroxyprogesterone acetate was compared with ganirelix to prevent ovulation; the number of mature eggs (15.1 against 14.6) and the stimulation length and dose were similar, and the trial met its non-inferiority margin.
Mechanism of Action
Ganirelix blocks the pituitary GnRH receptor, suppressing LH within hours, so it can be started partway through stimulation.
Immediate receptor block
No flare and no weeks of desensitisation: in the pivotal trial the GnRH drug ran a median 5 days against 26 for buserelin.
Short-acting
Peaks about an hour after injection, half-life about 13 to 16 hours, steady state after three days (label).
Less hyperstimulation
OHSS was 2.4% against 5.9% with buserelin in the European trial.
Published Research
The studies behind ganirelix, read from their PubMed abstracts: dose-finding, the pivotal trials against buserelin and leuprolide, protocol timing, offspring, and newer comparisons.
Dose-finding in 333 women
Across six doses, 0.25 mg had the highest implantation rate (21.9%) and an ongoing pregnancy rate of 33.8% per attempt; the 1 and 2 mg groups had early miscarriage rates of 12% to 13%.
Against a long agonist protocol
730 women were randomised 2:1 to ganirelix or intranasal buserelin with recombinant FSH. The median GnRH drug duration was 5 days against 26 and the median FSH dose 1,500 IU against 1,800, with stimulation a day shorter. LH rises occurred in 2.8% on ganirelix against 1.3%.
Against long leuprolide
Eggs retrieved were 11.6 against 14.1, fertilisation about 62% in both, clinical pregnancy 35.4% against 38.4%, with fewer moderate or severe injection-site reactions on ganirelix.
Poor responders: against microdose leuprolide
In a randomised pilot of 48 previous poor responders, the ganirelix protocol appeared as effective as the microdose agonist protocol and simpler for patients.
The babies
Follow-up of 333 women from a dose-finding study across six ganirelix doses found 68 ongoing pregnancies producing 73 infants, with six miscarriages (9%), a mean gestational age of 39.4 weeks for singletons, and one major congenital anomaly. The authors called it preliminary.
Fixed or flexible start
201 women predicted to respond strongly, without polycystic ovary syndrome, were randomised to start 0.25 mg on stimulation day 5 or by hormone and follicle criteria. Eggs retrieved were 16.7 against 17.5, with no difference in gonadotropin duration or dose.
In intrauterine insemination
Among 662 patients having intrauterine insemination with recombinant FSH, premature luteinisation occurred in 11.5%. Pregnancy rates were 22.4% in those affected and 17.7% in those not; giving the antagonist in a later cycle produced rates of 18% to 23%.
Egg donors: against medroxyprogesterone
Mature eggs retrieved were 15.1 with oral medroxyprogesterone and 14.6 with ganirelix, with similar stimulation, meeting the non-inferiority margin.
Dosing Data
Ganirelix is injected under the skin once daily in the mid to late follicular phase until the hCG trigger.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the trials above and the Ganirelix Acetate Injection prescribing information (DailyMed set 420ce739, version 2, effective May 11, 2026).
Contraindications & Cautions
A prescription injection used inside a monitored stimulation cycle.
Legal Status
Ganirelix is approved in the US, now only as generics.
Frequently Asked Questions
?What is ganirelix?
A synthetic ten-amino-acid GnRH antagonist. It blocks the pituitary receptor directly, suppressing LH within hours.
?What is it for?
Inhibiting premature LH surges in women undergoing controlled ovarian hyperstimulation — keeping an IVF cycle from ovulating before egg collection.
?Why did it change IVF?
Because an antagonist needs days rather than weeks. In the pivotal trial, the median GnRH drug duration fell from 26 days on a long agonist protocol to five.
?Is Antagon still sold?
No. The branded products have left the US market and the drug continues as generics, at the same 250 mcg daily dose.
?Why 250 mcg?
A dose-finding trial in 333 women found 0.25 mg gave the best implantation and pregnancy rates, while higher doses were linked to more early miscarriages.
?How long does it last?
The label gives a half-life of about 13 hours after one injection and 16 hours with daily dosing, with steady state after three days.
?Is it as effective as an agonist protocol?
Pregnancy rates were similar or slightly lower in head-to-head trials, with fewer injections, a shorter course and less hyperstimulation.
References
- [fda-pi] Ganirelix Acetate Injection Prescribing Information, Indications and Dosage sections (DailyMed version 2, effective May 11, 2026; read September 30, 2026).
- [pubmed] "A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group." Hum Reprod, 1998;13(11):3023-31. PMID: 9853849.
- [pubmed] Borm G, et al. "Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group." Hum Reprod, 2000;15(7):1490-8. PMID: 10875855.
- [pubmed] Fluker M, et al. "Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation." Fertil Steril, 2001;75(1):38-45. PMID: 11163814.
- [pubmed] Schmidt DW, et al. "A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders." Fertil Steril, 2005;83(5):1568-71. PMID: 15866609.
- [pubmed] Olivennes F, et al. "Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report." Hum Reprod, 2001;16(8):1588-91. PMID: 11473947.
- [pubmed] Luo X, et al. "Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial." BMC Pregnancy Childbirth, 2021;21(1):348. PMID: 33934703.
- [pubmed] Martinez-Salazar J, et al. "GnRH antagonist ganirelix prevents premature luteinization in IUI cycles: rationale for its use." Reprod Biomed Online, 2009;19(2):156-61. PMID: 19712548.
- [pubmed] Beguería R, et al. "Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial." Hum Reprod, 2019;34(5):872-880. PMID: 30927417.
- [other] US FDA, Drugs@FDA (openFDA): ganirelix acetate injection, ANDA 215658 (Gland), ANDA 216075 (Lupin), ANDA 204246 (Fyremadel, Sun), all prescription. Read September 30, 2026.
Sources & Citations
Studies were read from their PubMed records (October 6, 2026); the label and Drugs@FDA are listed below with their read dates.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.